The International Collaboration on Cosmetics Safety ushers in a new phase as its 2026 Board officers take their roles, strengthening its worldwide dedication to promoting animal-free innovations in cosmetics safety science amid swift regulatory and scientific shifts.
The International Collaboration on Cosmetics Safety (ICCS) has confirmed its 2026 Board officers after elections held during the organization’s December 2025 Board meeting, a milestone that underscores how this relatively young global initiative is solidifying its position in promoting scientifically robust, human‑relevant alternatives to animal testing in cosmetics safety assessment. The newly selected leadership reflects continuity as well as the organization’s growing sophistication, building on a year of significant accomplishments while positioning itself to expand its impact across regulatory, scientific, and industry communities worldwide.
ICCS operates at the intersection of science, policy, and collaboration, bringing together diverse stakeholders who share a common objective: accelerating the global adoption and acceptance of animal-free safety science for cosmetics and their ingredients. The confirmation of the 2026 Board officers underscores the organization’s intention to maintain strategic focus while navigating an increasingly complex international landscape, where expectations for ethical research, scientific rigor, and regulatory alignment continue to evolve.
Continued leadership stability and expansive global representation
The 2026 Board leadership unites senior leaders from the cosmetics, consumer goods, and regulatory advocacy fields, capturing the multi-stakeholder character that has shaped ICCS from the start. Stéphane Dhalluin, Ph.D., DABT, Global Head of Human & Environmental Safety Evaluation at L’Oréal, has been chosen again to serve as Chair of the Board of Directors. His renewed appointment reflects sustained trust in a leadership style grounded in scientific rigor, international collaboration, and productive dialogue with regulatory authorities.
Serving alongside him as Vice Chair is Darren Praznik, President and Chief Executive Officer of Cosmetics Alliance Canada, whose experience in industry representation and regulatory dialogue adds a valuable regional and policy-oriented perspective. The role of Secretary will be held by Heike Scheffler, Ph.D., Safety Advocacy and Regulatory Toxicology Director for Global Product Stewardship in Beauty and Oral Care at Procter & Gamble, bringing deep expertise in regulatory toxicology and global product safety frameworks. Michael Southall, Ph.D., Senior Director and Head of Global Toxicology and Clinical Safety within Medical Clinical & Safety Sciences at Kenvue, has been elected Treasurer, contributing extensive experience in toxicology leadership and governance.
Together, the officers form a Board leadership team that spans multinational corporations, industry associations, and regulatory science, reinforcing ICCS’ position as a neutral platform for collaboration rather than advocacy for any single sector. This balance is central to the organization’s credibility, particularly as it seeks to influence regulatory thinking and encourage convergence around animal-free safety methodologies.
Advancing animal-free science through collaboration
ICCS’ mission is grounded in the belief that animal-free safety assessment methods, once thoroughly optimized and validated, are not only ethically responsible but also capable of delivering exceptional scientific outcomes. Since its founding in early 2023, ICCS has worked to demonstrate that non-animal approaches can produce reliable, relevant data that protect both human health and the environment. The confirmation of the 2026 Board officers comes at a moment when this message is gaining strength, supported by tangible progress and growing involvement from regulators worldwide.
During 2025, ICCS delivered a series of initiatives that strengthened its scientific foundation and expanded its influence. Among these was the release of a Best Practice Guidance document, designed to provide clarity and consistency in the application of animal-free safety assessment approaches. This guidance aimed to bridge gaps between scientific innovation and regulatory expectations, offering a practical framework that stakeholders could reference when developing or evaluating non-animal data.
In parallel, ICCS contributed to shaping new methodologies consistent with next generation risk assessment (NGRA), an evolving framework that draws on advanced in vitro, in silico, and exposure-driven strategies. These methods are now widely regarded as fundamental to contemporary toxicology, offering more human-relevant insights while limiting dependence on animal studies. ICCS’ engagement in this field underscores its dedication to promoting both ethical progress and scientific rigor.
ICCS has also placed strong importance on open dialogue, and throughout 2025 the organization engaged widely with regulators, scientists, and policymakers in various regions, helping shape conversations about how animal-free data can be interpreted and integrated into current regulatory systems, a series of exchanges that has significantly advanced mutual understanding and confidence, especially in regions where the approval of non-animal approaches is still evolving.
A pivotal milestone reshaping the oversight of cosmetics safety
The selection of the 2026 Board officers unfolds amid a period of major shifts in global cosmetics regulation, as numerous markets revisit long‑standing testing mandates in response to evolving public expectations, scientific progress, and broader international policy developments. Within this landscape, organizations such as ICCS hold an essential role by helping bridge innovation and regulatory demands, ensuring that advancement remains both trustworthy and sustainable.
ICCS leadership has consistently emphasized that progress in animal-free safety science cannot arise from isolated efforts; instead, it requires coordinated action among industry, academia, regulators, and civil society. This perspective is reflected in the composition of the Board, which brings together leaders who understand the technical, regulatory, and organizational dimensions necessary to foster significant transformation.
Statements from ICCS leadership after the elections expressed both assurance and realism, highlighting the advances made in recent years while acknowledging that significant hurdles remain. They noted that securing broad regulatory approval for animal-free methods will continue to require ongoing research funding, transparent data exchange, and steady cooperation with authorities to respond to legitimate questions about reliability, practical applicability, and the protection of public health.
The re-elected Chair highlighted how crucial it is to harness ICCS’ global, multi-stakeholder framework to narrow the divide between innovation and regulation, ensuring that progress in animal-free science moves beyond laboratories and becomes reliable, consistently applicable tools that regulators can confidently use.
Reinforcing the groundwork for lasting influence
As ICCS looks ahead to 2026 and beyond, the organization is focused on consolidating its achievements while expanding its reach. The newly confirmed Board leadership is expected to play a central role in shaping priorities that balance scientific ambition with practical implementation. This includes identifying areas where additional guidance or consensus-building is needed, supporting the validation and communication of new methodologies, and fostering international alignment to reduce fragmentation in regulatory requirements.
Education remains another key pillar of ICCS’ strategy. By providing accessible, science-based resources and forums for discussion, the organization aims to demystify animal-free safety science and encourage informed decision-making. This is particularly important in a field where misconceptions or uneven understanding can slow progress, even when the underlying science is sound.
The organization’s structure, which includes market-leading cosmetics and ingredient manufacturers, trade and research associations, and animal protection organizations, positions it uniquely to address these challenges. This diversity of perspectives helps ensure that discussions remain grounded, balanced, and focused on shared goals rather than narrow interests.
Headquartered in New York, ICCS continues to operate as a global initiative, reflecting the inherently international nature of cosmetics development and regulation. Products and ingredients often move across borders, making harmonization and mutual recognition of safety approaches increasingly important. Through its collaborative model, ICCS seeks to contribute to this harmonization, reducing duplication and fostering trust in animal-free science worldwide.
In confirming its 2026 Board officers, ICCS signals both stability and forward momentum. The leadership team brings continuity from a year marked by concrete achievements, alongside the experience and perspective needed to navigate the next phase of change. As scientific innovation accelerates and regulatory expectations evolve, the organization’s role as a convener and catalyst for animal-free cosmetics safety science is set to become even more relevant.
Ultimately, the importance of the 2026 Board elections rests not only on who is selected, but also on what their leadership conveys: a continued dedication to cooperation, scientific rigor, and the ethical progress of alternatives to animal testing. For ICCS and its stakeholders, the years ahead present a chance to turn ambition into enduring results, guiding the evolution of cosmetics safety in a manner that brings ethics, scientific excellence, and global public confidence into alignment.
